Antibiotic Resistance Genes Among Carbapenem-resistant Enterobacterales (CRE) Isolates of Prapokklao Hospital, Chanthaburi Province, Thailand

References

• ElbadawiLI, BorlaugG, GundlachKM, et al. Carbapenem-resistant Enterobacteriaceae transmission in health care facilities-Wisconsin, February-May 2015. Morbid Mortal Wkly Rep. 2016;65(34):906–909. doi:10.15585/mmwr.mm6534a5
   Web of Science ®Google Scholar
• Suay-GarcíaB, Pérez-GraciaMT. Present and future of carbapenem resistant Enterobacteriaceae (CRE) infections. Antibiotics. 2019;8(3):122. doi:10.3390/antibiotics8030122
   Web of Science ®Google Scholar
• SheuCC, ChangYT, LinSY, ChenYH, HsuehPR. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80. doi:10.3389/fmicb.2019.0008030761114
   PubMed Web of Science ®Google Scholar
• JacobJT, KleinE, LaxminarayanR, et al. Vital signs: carbapenem-resistant Enterobacteriaceae. Morbid Mortal Wkly Rep. 2013;62(9):165.
   PubMed Web of Science ®Google Scholar
• TängdénT, GiskeCG. Global dissemination of extensively drug‐resistant carbapenemase‐producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277(5):501–512. doi:10.1111/joim.1234225556628
   PubMed Web of Science ®Google Scholar
• LiX, YeH. Clinical and mortality risk factors in bloodstream infections with carbapenem-resistant Enterobacteriaceae. Can J Infect Dis Med Microbiol. 2017. doi:10.1155/2017/6212910
   Web of Science ®Google Scholar
• NordmannP, NaasT, PoirelL. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791. doi:10.3201/eid1710.11065522000347
   PubMed Web of Science ®Google Scholar
• ShahidM, SobiaF, SinghA, KhanHM, MalikA, ShuklaI. Molecular epidemiology of carbapenem-resistant Enterobacteriaceae from a North Indian Tertiary Hospital. N Z J Med Lab Sci. 2012;66(1):5.
   Google Scholar
• GuhAY, BulensSN, MuY, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012–2013. JAMA. 2015;314(14):1479–1487. doi:10.1001/jama.2015.1248026436831
   PubMed Web of Science ®Google Scholar
• OkocheD, AsiimweBB, KatabaziFA, KatoL, NajjukaCF. Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS One. 2015;10(8):e0135745. doi:10.1371/journal.pone.013574526284519
   PubMed Web of Science ®Google Scholar
• XuY, GuB, HuangM, et al. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000–2012 in Asia. J Thorac Dis. 2015;7(3):376.25922715
   PubMed Web of Science ®Google Scholar
• AlotaibiFE, BukhariEE, Al-MohizeaMM, HafizT, EssaEB, AlTokhaisYI. Emergence of carbapenem-resistant Enterobacteriaceae isolated from patients in a university hospital in Saudi Arabia. Epidemiology, clinical profiles and outcomes. J Infect Public Health. 2017;10(5):667–673. doi:10.1016/j.jiph.2017.05.00428642140
   PubMed Web of Science ®Google Scholar
• AlmugadamBS, AliNO, AhmedAB. Prevalence and antibiotics susceptibility patterns of carbapenem resistant Enterobacteriaceae. J Bacteriol Mycol Open Access. 2018;6(3):187–190.
   Google Scholar
• ChotiprasitsakulD, SrichatrapimukS, KirdlarpS, PydenAD, SantanirandP. Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital. Infect Drug Resist. 2019;12:461. doi:10.2147/IDR.S19254030863128
   PubMed Web of Science ®Google Scholar
• KangJS, YiJ, KoMK, LeeSO, LeeJE, KimKH. Prevalence and risk factors of carbapenem-resistant Enterobacteriaceae acquisition in an emergency intensive care unit in a tertiary hospital in Korea: a Case-Control Study. J Korean Med Sci. 2019;34(18):18. doi:10.3346/jkms.2019.34.e140
   Web of Science ®Google Scholar
• TranDM, LarssonM, OlsonL, et al. High prevalence of colonisation with carbapenem-resistant Enterobacteriaceae among patients admitted to Vietnamese hospitals: risk factors and burden of disease. J Infect. 2019;79(2):115–122. doi:10.1016/j.jinf.2019.05.01331125639
   PubMed Web of Science ®Google Scholar
• LutgringJD, LimbagoBM, KraftCS. The problem of Carbapenemase-producing-carbapenem-resistant-Enterobacteriaceae detection. J Clin Microbiol. 2016;54(3):529–534. doi:10.1128/JCM.02771-1526739152
   PubMed Web of Science ®Google Scholar
• KostK, YiJ, RogersB, JerrisR. Comparison of clinical methods for detecting carbapenem-resistant Enterobacteriaceae. Pract Lab Med. 2017;8:18–25. doi:10.1016/j.plabm.2017.03.00228856222
   PubMedGoogle Scholar
• TacconelliE, CarraraE, SavoldiA, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-329276051
   PubMed Web of Science ®Google Scholar
• NARST. National antimicrobial resistance surveillance center, Thailand. Available from:http://narst.dmsc.moph.go.th/data/AMR%202000-2020-12M.pdf. Accessed 730, 2021. Thai.
   Google Scholar
• PartridgeSR, KwongSM, FirthN, JensenSO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev. 2018;31(4):e00088–17. doi:10.1128/CMR.00088-1730068738
   PubMed Web of Science ®Google Scholar
• NicolauDP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008;9(1):23–37. doi:10.1517/14656566.9.1.2318076336
   PubMed Web of Science ®Google Scholar
• LoganLK, WeinsteinRA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36. doi:10.1093/infdis/jiw28228375512
   PubMed Web of Science ®Google Scholar
• RhodesNJ, WagnerJL, DavisSL, et al. Trends in and predictors of carbapenem consumption across North American hospitals: results from a multicenter survey by the MAD-ID research network. Antimicrob Agents Chemother. 2019;63(7):e00327–19. doi:10.1128/AAC.00327-1931061154
   PubMed Web of Science ®Google Scholar
• BakthavatchalamYD, AnandanS, VeeraraghavanB. Laboratory detection and clinical implication of oxacillinase-48 like carbapenemase: the hidden threat. J Glob Infect Dis. 2016;8(1):41. doi:10.4103/0974-777X.17614927013843
   PubMed Web of Science ®Google Scholar
• LeeCR, LeeJH, ParkKS, KimYB, JeongBC, LeeSH. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol. 2016;7:895.27379038
   PubMed Web of Science ®Google Scholar
• WangQ, WangX, WangJ, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis. 2018;67(suppl_2):S196–S205. doi:10.1093/cid/ciy66030423057
   PubMed Web of Science ®Google Scholar
• ParkCE. Clinical laboratory aspect of carbapenem-resistant Enterobacteriaceae. Korean J Clin Lab Sci. 2020;52(1):18–27. doi:10.15324/kjcls.2020.52.1.18
   Google Scholar
• ChenWK, YangY, TanBH. Increased mortality among carbapenemase producing carbapenem-resistant Enterobacteriaceae carriers who developed clinical isolates of another genotype. Oxford Univ Press. 2019;6(2):ofz006.
   Google Scholar
• NetikulT, KiratisinP. Genetic characterization of carbapenem-resistant Enterobacteriaceae and the spread of carbapenem-resistant Klebsiella pneumoniae ST340 at a university hospital in Thailand. PLoS One. 2015;10(9):e0139116. doi:10.1371/journal.pone.013911626407326
   PubMed Web of Science ®Google Scholar
• NordmannP, GniadkowskiM, GiskeCG, PoirelL, WoodfordN, MiriagouV. European network on carbapenemases. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2012;18(5):432–438. doi:10.1111/j.1469-0691.2012.03815.x22507110
   PubMed Web of Science ®Google Scholar
• CheesbroughM. District Laboratory Practice in Tropical Countries, Part 2. Cambridge, UK: Cambridge University Press; 2005.
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• LeeHJ, ChoiJK, ChoSY, et al. Carbapenem-resistant Enterobacteriaceae: prevalence and risk factors in a single community-based hospital in Korea. Infect Chemother. 2016;48(3):166–173. doi:10.3947/ic.2016.48.3.16627659436
   PubMed Web of Science ®Google Scholar
• MohamedT, YousefLM, DarweeshEI, KhalilAK, MeghezelEM. Detection and characterization of carbapenem resistant Enterobacteriacea in Sohag University Hospitals. Egypt J Med Microbiol. 2018;27(4):61–69.
   Google Scholar
• ArsheewaW. Prevalence of carbapenemase enzyme in clinical isolates of carbapenem-resistant Enterobacteriaceae from Prapokklao Hospital in 2012–2013. J Prapokklao Hosp Clin Med Educ Cent. 2016;33(4):314–325.
   Google Scholar
• AlTamimiM, AlSalamahA, AlKhulaifiM, AlAjlanH. Comparison of phenotypic and PCR methods for detection of carbapenemases production by Enterobacteriaceae. Saudi J Biol Sci. 2017;24(1):155–161. doi:10.1016/j.sjbs.2016.07.00428053586
   PubMed Web of Science ®Google Scholar
• LivermoreDM, WarnerM, MushtaqS, DoumithM, ZhangJ, WoodfordN. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agent. 2011;37(5):415–419. doi:10.1016/j.ijantimicag.2011.01.012
   PubMed Web of Science ®Google Scholar
• Yeganeh SefidanF, AzargunR, GhotaslouR. Fosfomycin, a therapeutic option for infections produced by multiple drug-resistant Enterobacteriaceae. Microb Res. 2016;7(1):32–36. doi:10.4081/mr.2016.6407
   Google Scholar
• GopichandP, AgarwalG, NatarajanM, et al. In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections. Infect Drug Res. 2019;12:2005. doi:10.2147/IDR.S207569
   Web of Science ®Google Scholar
• MączyńskaB, PalecznyJ, Oleksy-WawrzyniakM, Choroszy-KrólI, BartoszewiczM. In vitro susceptibility of multi-drug resistant Klebsiella pneumoniae strains causing nosocomial infections to fosfomycin. a comparison of determination methods. Pathogens. 2021;10(5):512. doi:10.3390/pathogens1005051233922754
   PubMed Web of Science ®Google Scholar
• RattanaumpawanP, ChooratC, TakonkitsakulK, TangkoskulT, SeenamaC, ThamlikitkulV. A prospective surveillance study for multidrug-resistant bacteria colonization in hospitalized patients at a Thai University Hospital. Antimicrob Resist Infect Control. 2018;7(1):1–11. doi:10.1186/s13756-018-0393-229312658
   PubMed Web of Science ®Google Scholar
• RimrangB, ChanawongA, LulitanondA, et al. Emergence of NDM-1-and IMP-14a-producing Enterobacteriaceae in Thailand. J Antimicrob Chemother. 2012;67(11):2626–2630. doi:10.1093/jac/dks26722796889
   PubMed Web of Science ®Google Scholar
• KerdsinA, DeekaeS, ChayangsuS, et al. Genomic characterization of an emerging blaKPC-2 carrying Enterobacteriaceae clinical isolates in Thailand. Sci Rep. 2019;9(1):1–7. doi:10.1038/s41598-019-55008-x30626917
   PubMedGoogle Scholar
• CannasS, UsaiD, PinnaA, et al. Essential oils in ocular pathology: an experimental study. J Infect Dev Ctries. 2015;9(6):650–654. doi:10.3855/jidc.684226142676
   PubMed Web of Science ®Google Scholar
• RameshkumarG, RamakrishnanR, ShivkumarC, et al. Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing gram-negative bacteria isolated from ocular infections. Indian J Ophthalmol. 2016;64(4):303. doi:10.4103/0301-4738.18294327221683
   PubMed Web of Science ®Google Scholar
• PinnaA, DonaduMG, UsaiD, et al. In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6%(IODIM®). Acta Ophthalmol. 2020;98(2):e178–e180. doi:10.1111/aos.1424331486592
   PubMed Web of Science ®Google Scholar
• PinnaA, DonaduMG, UsaiD, DoreS, BosciaF, ZanettiS. In vitro antimicrobial activity of a new ophthalmic solution containing hexamidine diisethionate 0.05%(keratosept). Cornea. 2020;39(11):1415–1418. doi:10.1097/ICO.000000000000237532452982
   PubMed Web of Science ®Google Scholar